Canakinumab May Reduce CV Events in Patients Post-MI With Residual Inflammatory Risk

Share this content:
Canakinumab significantly reduced the total number of CV events in patients with prior MI and residual inflammatory risk.
Canakinumab significantly reduced the total number of CV events in patients with prior MI and residual inflammatory risk.

The following article is part of conference coverage from the 2018 AHA Scientific Sessions in Chicago, Illinois.The Cardiology Advisor's staff will be reporting breaking news associated with research conducted by leading experts in cardiology. Check back for the latest news from AHA 2018.

CHICAGO — Anti-inflammatory therapy with the interleukin-1β inhibitor canakinumab may drastically reduce cardiovascular event risk in individuals with a previous myocardial infarction (MI) and evidence of lingering inflammatory risk, according to study results shared at AHA 2018, Scientific Sessions of the American Heart Association, a conference held on November 10-12.

In total, 10,061 patients were randomly assigned to receive placebo or canakinumab 50 mg, 150 mg, or 300 mg once every three months. A composite of serious cardiovascular events including non-fatal MI, non-fatal-stroke, need for coronary revascularization, and cardiovascular death was then analyzed in each treatment group.

Canakinumab was shown to reduce serious cardiovascular events with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg canakinumab groups of 10.4, 8.4, 8.3, and 8.3, respectively.

The reduction in recurrent events resulted from decreases in coronary revascularization for the 50 mg (relative risk [RR], 0.73; 95% CI, 0.61-0.88), 150 mg (RR, 0.73; 95% CI, 0.61-0.88) and 300 mg (RR, 0.70; 95% CI, 0.59-0.84) doses and from decreases in myocardial infarction for the 150 mg (RR, 0.75; 95% CI, 0.61-0.93) and 300 mg (RR, 0.80; 95% CI, 0.65-0.98) doses.

"Anti-inflammatory therapy with canakinumab significantly reduced the total number of cardiovascular events in patients with prior MI and evidence of residual inflammatory risk," the researchers concluded.

Disclosure: Multiple authors declare affiliations with drug companies. See reference for a full list of disclosures.

For more coverage of AHA 2018, click here.

Reference

Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker P. Anti-inflammatory therapy with canakinumab and reduction in total cardiovascular events. Presented at AHA 2018, Scientific Sessions of the American Heart Association; November 10-12, 2018; Chicago, IL. Abstract Number: Sa2099/2099.

You must be a registered member of The Cardiology Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-Newsletters